The bone marrow niche has mystified scientists for many years, leading to widespread
investigation to shed light into its molecular and cellular composition. Considerable efforts …

Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …

AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active
against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor …

Success with transplantation of autologous hematopoietic stem and progenitor cells
(HSPCs) in patients depends on adequate collection of these cells after mobilization from …

As more efficient agents for stem cell mobilization are being developed, there is an urgent
need to define which patient population might benefit from these novel drugs. For a precise …

Abstract AMD3100 (plerixafor), a CXCR4 antagonist, has opened a variety of avenues for
potential therapeutic approaches in different refractory diseases. The CXCL12/CXCR4 axis …

Peripheral blood progenitor cell mobilization practices vary significantly among institutions.
Effective mobilization regimens include growth factor alone, chemotherapy and growth factor …

Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization.
Identification of poor mobilizers (PMs) would provide a tool for early intervention with new …

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in
patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty …

Successful hematopoietic stem cell transplant requires the infusion of a sufficient number of
hematopoietic stem/progenitor cells (HSPCs) that are capable of homing to the bone marrow …